Aberrant_JJ
splicing_NN
of_IN
the_DT
TSG101_NN
and_CC
FHIT_NN
genes_NNS
occurs_VBZ
frequently_RB
in_IN
multiple_JJ
malignancies_NNS
and_CC
in_IN
normal_JJ
tissues_NNS
and_CC
mimics_VBZ
alterations_NNS
previously_RB
described_VBN
in_IN
tumors_NNS
._.

Intragenic_JJ
deletions_NNS
of_IN
TSG101_NN
,_,
the_DT
human_JJ
homolog_NN
of_IN
a_DT
mouse_NN
gene_NN
-LRB-_-LRB-
tsg101_NN
-RRB-_-RRB-
that_WDT
acts_VBZ
to_TO
suppress_VB
malignant_JJ
cell_NN
growth_NN
,_,
were_VBD
reported_VBN
in_IN
human_JJ
breast_NN
tumors_NNS
._.

We_PRP
screened_VBD
TSG101_NN
for_IN
somatic_JJ
mutations_NNS
in_IN
DNA_NN
and_CC
RNA_NN
samples_NNS
isolated_VBN
from_IN
a_DT
variety_NN
of_IN
common_JJ
human_JJ
malignancies_NNS
,_,
EBV-immortalised_JJ
B-cells_NNS
,_,
and_CC
normal_JJ
lung_NN
parenchyma_NN
._.

Intragenic_JJ
TSG101_NN
deletions_NNS
in_IN
RNA_NN
transcripts_NNS
were_VBD
frequently_RB
found_VBN
in_IN
all_DT
types_NNS
of_IN
samples_NNS
._.

Analysis_NN
of_IN
DNA_NN
failed_VBD
to_TO
show_VB
genomic_JJ
rearrangements_NNS
corresponding_VBG
to_TO
transcripts_NNS
containing_VBG
deletions_NNS
in_IN
the_DT
same_JJ
samples_NNS
._.

The_DT
breakpoints_NNS
of_IN
most_JJS
transcript_NN
deletions_NNS
coincide_VBP
with_IN
genuine_JJ
or_CC
cryptic_JJ
splice_NN
site_NN
sequences_NNS
,_,
suggesting_VBG
that_IN
they_PRP
result_VBP
from_IN
alternative_JJ
or_CC
aberrant_JJ
splicing_NN
._.

A_DT
similar_JJ
spectrum_NN
of_IN
transcript_NN
deletions_NNS
has_VBZ
previously_RB
been_VBN
described_VBN
in_IN
the_DT
putative_JJ
tumor_NN
suppressor_NN
gene_NN
FHIT_NN
._.

We_PRP
analyzed_VBD
FHIT_NN
in_IN
the_DT
same_JJ
series_NN
of_IN
RNA_NN
samples_NNS
and_CC
detected_VBD
truncated_JJ
FHIT_NN
transcripts_NNS
frequently_RB
in_IN
both_CC
tumor_NN
and_CC
normal_JJ
tissues_NNS
._.

In_IN
addition_NN
,_,
transcripts_NNS
from_IN
TSG101_NN
,_,
FHIT_NN
and_CC
seven_CD
other_JJ
genes_NNS
were_VBD
analyzed_VBN
in_IN
RNA_NN
isolated_VBN
from_IN
normal_JJ
peripheral_JJ
blood_NN
lymphocytes_NNS
._.

Large_JJ
TSG101_NN
and_CC
FHIT_NN
intragenic_JJ
transcript_NN
deletions_NNS
were_VBD
detected_VBN
and_CC
these_DT
appeared_VBD
to_TO
be_VB
the_DT
predominant_JJ
transcript_NN
in_IN
'_``
aged_JJ
'_''
lymphocytes_NNS
._.

Similar_JJ
alterations_NNS
were_VBD
not_RB
detected_VBN
in_IN
transcripts_NNS
of_IN
the_DT
other_JJ
genes_NNS
which_WDT
were_VBD
analyzed_VBN
._.

Our_PRP$
findings_NNS
demonstrate_VBP
that_IN
truncated_VBN
TSG101_NN
and_CC
FHIT_NN
transcripts_NNS
are_VBP
commonly_RB
detected_VBN
in_IN
both_CC
normal_JJ
and_CC
malignant_JJ
tissues_NNS
and_CC
that_IN
a_DT
significant_JJ
fraction_NN
of_IN
these_DT
are_VBP
likely_JJ
to_TO
be_VB
the_DT
result_NN
of_IN
aberrant_JJ
splicing_NN
._.

While_IN
we_PRP
can_MD
not_RB
exclude_VB
that_IN
alterations_NNS
in_IN
TSG101_NN
and_CC
FHIT_NN
occur_VBP
during_IN
cancer_NN
development_NN
,_,
our_PRP$
data_NNS
indicate_VBP
that_IN
in_IN
this_DT
context_NN
the_DT
commonly_RB
observed_VBN
transcript_NN
abnormalities_NNS
are_VBP
misleading_JJ
._.

